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Abstract
Background: The usefulness of adjuvant chemotherapy for stage II colon cancer has not been established. Meanwhile,
the presence of stage II colon cancer with high-risk factors for recurrence has been reported. To our knowledge, no
prospective study of adjuvant chemotherapy for stage II colon cancer with high-risk factors has been implemented to
date. Patients and Methods: This study is a prospective nonrandomized controlled study based on patients’ selection
of treatment option, including randomized therapeutic decision-making, to evaluate the usefulness of adjuvant
chemotherapy with tegafur-uracil (UFT) with leucovorin (LV) for stage II colon cancer with high-risk factors for recurrence,
compared with surgery alone. Five courses of UFT/LV therapy will be given as follows: UFT (300 mg/m2/d) with LV (75
mg/d) will be orally administered in 3 doses per day. Treatment will be received daily for 28 days, followed by a 7-day rest
or will be received daily for 5 days, followed by a 2-day rest. For both regimens, 1 course will last 5 weeks, and 5 courses
will be given. The primary end point is disease-free survival. A propensity score matching will be conducted based on 7
variables that represent risk factors to minimize selection bias in a comparison between the nonrandomized arms. For
this nonrandomized comparison, a target sample size is set at 1200 (400 and 800 patients for the surgery alone and UFT/
LV groups, respectively) and 1720 patients will be enrolled. In this study we aim to evaluate the therapeutic usefulness of
adjuvant chemotherapy with UFT/LV for stage II colorectal cancer with risk factors for recurrence.
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278 -Introduction 6-year OS were signiﬁcantly better in the FOLFOX4 group
Standard adjuvant chemotherapy for stage III colon cancer consists
of 6 months of treatment with ﬂuorouracil (5-FU) with leucovorin
(LV), tegafur-uracil (UFT) with LV, capecitabine, and infusional
ﬂuorouracil and folinic acid with oxaliplatin (FOLFOX).1 As for the
efﬁcacy of adjuvant chemotherapy for stage II colorectal cancer,
positive reports2 and negative reports3 have been published, and a
deﬁnitive consensus has not been reached. Therefore, for stage II
colon cancer, the standard treatment is considered to be surgery alone.
Among patients with stage II colorectal cancer, the presence of a
subgroup with risk factors for recurrence has been reported. The
American Society of Clinical Oncology 2004 guidelines, the Eu-
ropean Society for Medical Oncology guidelines, and the National
Comprehensive Cancer Network guidelines propose the following
risk factors for recurrence: the presence of < 12 dissected lymph
nodes, T4 disease, bowel perforation, and poorly differentiated
adenocarcinoma and mucinous carcinoma.4-6 In addition, the
presence of circulating tumor cells (CTCs) in peripheral blood  24
hours after surgery has been reported to be an independent risk
factor.7 Positivity for Carcinoembryonic antigen (CEA) mRNA has
been proposed as a surrogate marker for CTCs.8 However, there has
been no prospective study of adjuvant chemotherapy for patients
with risk factors for recurrence such as those listed herein.
The Multicenter International Study of Oxaliplatin/5-Fluoro-
uracil/Leucovorin in the Adjuvant Treatment of Colon Cancer
(MOSAIC) study was a randomized clinical trial that compared 5-
FU/LV with FOLFOX4 for stage II/III colon cancer.9 An additive
effect of oxaliplatin was obtained with respect to 5-year disease-
free survival (DFS) and 6-year overall survival (OS). However,
when analyzed according to the disease stage, 5-year DFS andFigure 1 Study Schema. Clinical Trial on the Efﬁcacy of UFT/LV for
Japanese Foundation for Multidisciplinary Treatment of C
Patient Registration in the Trial
Abbreviations: CEA ¼ Carcinoembryonic antigen; UFT/LV ¼ Tegafur-Uracil With Leucovorin.
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signiﬁcantly among patients with stage II colon cancer. UFT/LV
for stage II/III colon cancer demonstrated DFS and OS similar to
5-FU/LV in The National Surgical Adjuvant Breast and Bowel
Project (NSABP) C-06.10 UFT/LV has been widely used in
Japan. The effectiveness of UFT/LV for stage III colon cancer was
demonstrated to be noninferior in 3-year DFS compared with
that of 5-FU/LV in Japan Clinical Oncology Group (JCOG)
0205.11 In the present study, we have planned and started to
conduct a clinical trial to compare adjuvant chemotherapy with
UFT/LV with surgery alone in patients with stage II colon cancer
at high risk for recurrence.
Study Design
The study is a nonrandomized controlled study based on patients’
selection of treatment to evaluate the usefulness of adjuvant
chemotherapy with UFT/LV for stage II colon cancer with high risk
for recurrence compared with surgery alone. Because there is no
evidence to indicate that adjuvant chemotherapy is clearly advisable
for stage II colon cancer at high risk for recurrence, it was considered
difﬁcult to obtain informed consent when the study used a ran-
domized controlled design. Therefore, we conducted a non-
randomized study that would allow patients to choose whether to
receive treatment of surgery alone (group A) or with UFT/LV (group
B). Patients who are unable to choose treatment are randomly
assigned to surgery alone (group C) or UFT/LV (group D; Figure 1).
The primary end point is DFS. Secondary end points are OS,
safety, effects on positivity for CEA mRNA  24 hours after sur-
gery, and outcomes.Stage II Colorectal Cancer With Risk Factors for Recurrence:
ancer 46-1201. CEA mRNA to Be Measured Within 14 Days of
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Approximately 300 leading Japanese institutions and hospitals
will participate in the study after approval by the internal review
board of each institution.
Eligibility Criteria
The inclusion criteria are as follows:
(1) Histologically conﬁrmed stage II colon adenocarcinoma
(2) At least 1 of the following factors: T4 disease
 Perforation/penetration
 Poorly differentiated adenocarcinoma
 Mucinous carcinoma
 Fewer than 12 dissected lymph nodes(3) R0 resection
(4) Age 20 to 80 years
(5) Eastern Cooperative Oncology Group performance status
of 0 or 1
(6) No previous treatment other than surgery for the colon
cancer
(7) Adequate oral intake
(8) Adequate organ functions as listed: Leukocytes:  3000/mm3 to < 12,000/mm3
 Neutrophils:  1500/mm3
 Platelets:  100,000/mm3
 Hemoglobin:  9.0 g/dL
 Total bilirubin:  2.0 mg/dL
 Aspartate aminotransferase and alanine
aminotransferase:  100 IU/L
 Serum creatinine: < 1.5 mg/dL
(9) Treatment can be started within 8 weeks after surgery
(10) Written informed consent.
The exclusion criteria are as follows:
(1) Contraindications for UFT/LV
(2) Multiple active cancers with a disease-free period of < 5
years
(3) Serious postoperative complications
(4) Presence of any of the following comorbidities: Uncontrolled diabetes mellitus
 Uncontrolled hypertension
 Hepatic cirrhosis or hepatic failure
 Renal failure
 Interstitial pneumonia, pulmonary ﬁbrosis, or severe
emphysema
 Active infection
 Heart failure, myocardial infarction, angina pectoris, or
marked electrocardiogram abnormalities within the pre-
vious 6 months(5) Serious diarrhea
(6) History of serious drug hypersensitivity
(7) Concern about pregnancy
(8) Psychosis or psychiatric symptoms
(9) Other reasons as speciﬁed by the attending physician.Treatment Plan
Groups A and C (Surgery Alone)
Patients are followed-up without adjuvant treatment according to
a surveillance schedule that includes chest and abdominal computed
tomography scans every 6 months, for 5 years until recurrence,
other malignancy, or death is conﬁrmed.
Groups B and D (UFT/LV)
Tegafur-uracil/LV will be started within 8 weeks after surgery.
Five courses of UFT/LV therapy will be given as follows: UFT
(300 mg/m2/d) with LV (75 mg/d) orally administered in 3 doses
per day at approximately 8-hour intervals. Treatment will be
received daily for 28 days, followed by a 7-day rest (daily treatment
regimen) or will be received daily for 5 days, followed by a 2-day rest
(5-day treatment plus 2-day rest regimen; no treatment on Satur-
days and Sundays). For both regimens, 1 course will last 5 weeks,
and 5 courses will be given.
After the completion of UFT/LV therapy, patients are followed-
up according to the same schedule as for groups A and C.
Target Sample Size
The sample size will be determined separately for the non-
randomized arms and the randomized arms, using the same clinical
hypotheses. The 3-year DFS is forecast to be 78% in the surgery-
alone group and 84% (hazard ratio [HR], 0.7) in the UFT/LV
group of this study.
The sample size in the nonrandomized arm (groups A and B),
assuming a registration period of 3 years, a follow-up period of 5 years,
a 2-sided a level of .05, a power of 80%, and a sample size ratio of 1:2
between the surgery-alone group and theUFT/LV group, is estimated
to be 1122 subjects in total. Because some dropouts are expected, the
target sample size has been set at 1200 in total (400 in the surgery-
alone group and 800 in the UFT/LV group). In other words, the
target number of patient pairs to be used for propensity matching has
been set at 400. The patient enrollment will be completed when 400
pairs of patients are determined to be analyzed.
Based on prestudy exploratory investigation of historical data at 1
hospital, we expect the matching rate to be 70% at maximum. With
this matching rate of 70%, 1715 patients are needed to be enrolled.
Considering that this expectation contains substantial uncertainty,
we plan to reestimate the number of patients to be accrued by
periodically monitoring the matching rate. If the matching rate is
more likely to decrease to 60% or 50%, we will increase the number
of accrual patients to 2000 or 2400 accordingly.
Statistical Analysis Plan
The ﬁnal data analysis will be conducted separately for the non-
randomized arms (group A vs. group B) and randomized arms (group
C vs. group D). For analysis of the nonrandomized arm, propensity
score matching will be used to minimize confounding in compari-
sons.12 The potential confounding factors for estimating propensity
scores are prespeciﬁed as follows: age ( 70 or < 70), sex (male or
female), number of dissected lymph nodes ( 12 or< 12), T4 disease
(presence or absence), bowel perforation (presence or absence), poorly
differentiated adenocarcinoma (presence or absence), and mucinous
carcinoma (presence or absence). The caliper of the propensity scoreClinical Colorectal Cancer December 2015 - 279
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280 -matching will be determined before the analysis so that the stan-
dardized differences of all confounding factors will be < 0.1.13
Moreover, analysis will be conducted with the inverse probability of
treatment-weighting method,14 based on propensity scores.
The analysis plan for the nonrandomized arms is as follows: a
stratiﬁed log-rank test will be used to compare arms, taking into
account strata for matched pairs in populations to which propensity
score matching is applied (2-sided, signiﬁcance level of 5%). The
HR and 2-sided 95% conﬁdence interval (CI) in the UFT/LV
group will be calculated using the stratiﬁed Cox proportional haz-
ards model. The KaplaneMeier method will be used to estimate 3-
year DFS for each arm and Greenwood formula to calculate the
95% CI. In addition, to examine the inﬂuence of interinstitutional
variability on the comparison, a sensitivity analysis will be done by
excluding hospitals in which > 10 patients are enrolled and more
than 80% of them are in either of the surgery-alone and UFT/LV
groups. This study is registered with UMIN-CTR, protocol ID:
UMIN000007783.
Conclusion
The study is a nonrandomized controlled study based on pa-
tients’ selection of treatment options to evaluate the usefulness of
adjuvant chemotherapy with UFT/LV after curative resection of
stage II colon cancer in patients who might be at high risk for
recurrence, compared with surgery alone, using propensity score
matching in the analysis. Enrollment in this study began in May
2012 and is under way.Acknowledgments
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